News & Events

From the category archives: Omega News

News

FDA submission for Emergency Use Authorisation

Omega announces that following completion of the of US performance studies, its technology partner, Mologic Ltd has filed its submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorisation for its rapid point-of-care COVID-19 antigen test, for use under both the Omega’s VISITECT® brand and Global Access Diagnostics (GAD) brand.

Read the full RNS here

Update on UK Government manufacturing contract

The Company remains in regular dialogue with the Department of Health and Social Care to provide manufacturing capacity for COVID-19 lateral flow antigen tests utilising the key pieces of manufacturing equipment loaned by the UK Government for that purpose.

Read the full RNS here

Launch of VISITECT® COVID-19 Antigen & Update

Omega launches our VISITECT® COVID-19 Antigen test, a rapid point-of-care diagnostic test for the detection of active COVID-19 infections.

Read the full RNS here

CE-Mark of Mologic COVID-19 lateral flow antigen test

Omega announces that it has CE-Marked Mologic Ltd’s lateral flow antigen test for COVID-19, to be sold for professional-use under Omega’s VISITECT® brand.

Read the full RNS here

UK Public Sector Contract disclosure

Omega's contract with DHSC to provide manufacturing capacity for COVID-19 lateral flow antigen tests estimated at £374 million.

Read the full RNS here

Contract with Screen4 for COVID-19 antibody laboratory-based testing service

Omega announces that it has signed a contract with Screen4 Ltd to provide a testing service using the Mologic ELISA antibody test for COVID-19 from our in-house testing laboratory in Littleport, Cambridgeshire. This follows the launch of the COVID-19 antibody testing service, as announced on 26 January 2021.

Read the full RNS here

Directorate Change

We are pleased to announce the appointment of Dr Simon Douglas as independent Non-Executive Chairman. Simon has been appointed to the Board with immediate effect and has also become a member of both the Audit Committee and the Remuneration Committee.

Read the full RNS here

UK Government manufacturing contract

Omega announces that it has agreed a contract with the Department of Health and Social Care to provide manufacturing capacity for COVID-19 lateral flow antigen tests, as part of the UK Government’s well-publicised target of producing two million lateral flow tests per day.

Read the full RNS here

Launch of COVID-19 antibody laboratory-based testing service

We are pleased to announce that we have launched the Mologic ELISA antibody test for COVID-19 through our in-house testing laboratory service in Littleport, Cambridgeshire.

Read the full RNS here

Update re AbC-19™ Rapid Test

Omega notes today’s update from Abingdon Health regarding the AbC-19™ Rapid Test and welcomes confirmation that they continue to work constructively with the Medicines and Healthcare products Regulatory Agency to try to enable approval for home use and self-test of the AbC-19™ Rapid Test in the UK.

Read the full RNS here

Pages: Previous123NextReturn Top